Print this page
-
A Phase 1b Multicenter, Open-label, Study of JNJ-90009530, an Autologous Anti-CD20
CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non- Hodgkin Lymphoma
Protocol: 012317Principal Investigator:
- Matthew Matasar (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in
Participants with B-cell Malignancies
Protocol: 012321Principal Investigator:
- Joanna Rhodes MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants with Advanced Malignancies
Protocol: 052310Principal Investigator:
- Sanjay Goel (Rutgers University)
Applicable Disease Sites: Any Site -
NCI 10204 - A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Protocol: 092305Principal Investigator:
- Sarah Weiss MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Melanoma, Skin